Antiretroviral Therapy, Highly Active
"Antiretroviral Therapy, Highly Active" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drug regimens, for patients with HIV INFECTIONS, that aggressively suppress HIV replication. The regimens usually involve administration of three or more different drugs including a protease inhibitor.
| Descriptor ID |
D023241
|
| MeSH Number(s) |
E02.319.310.075
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antiretroviral Therapy, Highly Active".
Below are MeSH descriptors whose meaning is more specific than "Antiretroviral Therapy, Highly Active".
This graph shows the total number of publications written about "Antiretroviral Therapy, Highly Active" by people in this website by year, and whether "Antiretroviral Therapy, Highly Active" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2004 | 1 | 0 | 1 |
| 2005 | 0 | 2 | 2 |
| 2006 | 1 | 2 | 3 |
| 2007 | 4 | 4 | 8 |
| 2008 | 11 | 7 | 18 |
| 2009 | 9 | 4 | 13 |
| 2010 | 9 | 15 | 24 |
| 2011 | 13 | 7 | 20 |
| 2012 | 21 | 8 | 29 |
| 2013 | 14 | 12 | 26 |
| 2014 | 14 | 11 | 25 |
| 2015 | 12 | 8 | 20 |
| 2016 | 11 | 9 | 20 |
| 2017 | 10 | 8 | 18 |
| 2018 | 10 | 9 | 19 |
| 2019 | 5 | 6 | 11 |
| 2020 | 7 | 8 | 15 |
| 2021 | 2 | 5 | 7 |
| 2022 | 0 | 1 | 1 |
| 2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antiretroviral Therapy, Highly Active" by people in Profiles.
-
Transition to dolutegravir-based ART in 35 low- and middle-income countries: a global survey of HIV care clinics. AIDS. 2024 Dec 01; 38(15):2073-2085.
-
DORA: 48-week weight and metabolic changes in Black women with HIV, in a phase IIIb switch study from dolutegravir- or efavirenz- to doravirine-based first-line antiretroviral therapy. HIV Med. 2025 Jan; 26(1):81-96.
-
Home delivery of ART: could this be a reality in South Africa? Lancet HIV. 2022 12; 9(12):e812-e814.
-
Predictors of Transition to Frailty in Middle-Aged and Older People With HIV: A Prospective Cohort Study. J Acquir Immune Defic Syndr. 2021 12 15; 88(5):518-527.
-
Pharmacist-initiated antiretroviral therapy (PIMART). S Afr Med J. 2021 12 02; 111(12):1162-1163.
-
Perceived efficacy of HIV treatment-as-prevention among university students in Johannesburg, South Africa. Sex Transm Infect. 2021 12; 97(8):596-600.
-
Maternal HIV infection is associated with distinct systemic cytokine profiles throughout pregnancy in South African women. Sci Rep. 2021 05 12; 11(1):10079.
-
Economic evaluation of differentiated service delivery models for HIV treatment in Lesotho: costs to providers and patients. J Int AIDS Soc. 2021 04; 24(4):e25692.
-
Linking the timing of a mother's and child's death: Comparative evidence from two rural South African population-based surveillance studies, 2000-2015. PLoS One. 2021; 16(2):e0246671.
-
Differential Responsiveness of the Platelet Biomarkers, Systemic CD40 Ligand, CD62P, and Platelet-Derived Growth Factor-BB, to Virally-Suppressive Antiretroviral Therapy. Front Immunol. 2020; 11:594110.